IllumeSense What?
IllumeSense Why?
IllumeSense How?

Consumers need reliable information from a trusted clinician, and safe products, to make better decisions for their health and that of their families

  • The complexity of clinical data acquisition, strategies and analysis
  • Lack of data analytics tools for better cannabis care outcomes
  • Lack of patient trust and engagement due to societal stigma
  • Difficulty in identifying verified, quality products
  • Limited cannabis educated healthcare professionals

Health data analytics software platform brings clinicians, consumers and indusrty

  • Real-world health data insights for discovery
  • Clinical decision-support tool for clinicians
  • Evidence-based data for better health outcomes​
  • Applied Machine Learning to enhance human-centric decision process
  • Customized, interactive data to generate actionable insights


To build an AI-facilitated health data analytics platform that will improve cannabinoid healthcare and accelerate science


To be the cannabinoid data analytics platform for reliable care, high-quality products, and sound policy standards


To share knowledge with the next generation of cannabinoid consumers

2018 Cannabis Highlights By Numbers
2018 US Cannabis And Alcohol Sales

Clinicians: Your intelligent Electronic Health Record and Telehealth software platform is designed by clinicians like you to generate real-world data insights for Clinical Decision Support.

Brands: Engage, educate, retain and empower your wellness and medical consumers. Connect them with clinicians trained in CBD and Cannabis care for reliable information.

Our platform can be your research study partner powered by Human-centric AI (HAI), where you can test the efficacy of products used by your consumers for differentiation.

  • Current legal states are forecasting to grow to $30 billion by 2025.
  • Millions of wellness consumers are interested in evidence-based health effect data for the products to enter the market.
  • 1 out of 7 Americans tried CBD products in 2019.
  • 14% of Americans say they use CBD products for various conditions such as pain an anxiety.
  • 4 in 10 Americans say CBD should be Over the Counter (OTC) medicine.

Sources: UPI, GALLUP, New Frontier Data